CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Drug Reimbursement Recommendation - glucagon (Baqsimi)

Published on: January 24, 2020
Result type: News

Today, CADTH has issued final recommendations for:

glucagon (Baqsimi)

Indications: Severe hypoglycemic reactions
Recommendation: Reimburse with clinical criteria and/or conditions

For more information